Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BioAge Labs, Inc.

NASDAQ: BIOA · Life Sciences · 3 alerts · CIK 1709941

Share price
$5.22Close, Nov 16
Market cap
$240M
Shares outstanding
45.96MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioAge Labs, Inc. filings on SEC EDGAR ↗

4:41 PM ET 10-Q
Financial Results

BioAge Labs Q3 2026 Results: Net Loss of $33.5M, Loss Widens

BioAge Labs reported a net loss of $81.9 million for the nine months ended September 30, 2026, compared to $54.7 million for the same period in 2025, driven primarily by a significant increase in research and development expenses. The company strengthened its balance sheet through an underwritten stock offering and at-the-market sales, ending the period with $352.3 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $33.5M
4:36 PM ET 8-K
Financial Results

BioAge Labs Financial Results

BioAge Labs reported third quarter 2026 financial results, highlighting the dosing of the first participant in its Phase 2 QUELL-DME trial for diabetic macular edema. The company also completed enrollment in its Phase 2 QUELL-CV trial for obesity and inflammation, with topline data expected in Q4 2026.

Term
Q3 2026

“NLRP3 is a key switch that turns on inflammation and drives multiple diseases. Injectable drugs that block two major inflammatory signals, IL-1 and IL-6, are already approved for multiple indications, but a once-daily pill that works earlier in the process—and also lowers IL-18 and reduces harmful inflammatory cell death—could help many more people. That is the opportunity we are pursuing with BGE-102.”

Kristen Fortney, Ph.D., CEO and co-founder of BioAge
4:15 PM ET 8-K
Clinical Trial Data

BioAge Labs Clinical Trial Data

BioAge Labs announced the first participant has been dosed in its QUELL-DME Phase 2 clinical trial evaluating BGE-102, an oral NLRP3 inhibitor, for the treatment of diabetic macular edema. The 180-participant trial will evaluate the drug as both a monotherapy and in combination with anti-VEGF therapy, with topline results expected in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.